J&K Battles Record 11,950 TB Cases in 2025 as Post-Pandemic Detection Efforts Reveal Persistent Disease Burden
By Rohini Singh IIMC Jammu
Jammu & Kashmir recorded 11,950 tuberculosis cases in 2025, the highest annual figure in the past seven years. This is the peak that has caused the Union Territory’s government to have visibly intensified efforts to strengthen detection, reporting, and treatment systems following earlier trends that showed disruptions and rising pressure on the health system.
After years of pandemic-induced fluctuations, Jammu & Kashmir’s fight against tuberculosis (TB) has entered a critical new phase. While the figure marks a significant rise from the 11,402 cases recorded in the pre-pandemic year of 2019, it highlights a complex interplay between a persistent disease burden and a healthcare system finally catching up with missed diagnoses.
Between 2020 and 2021, Jammu & Kashmir saw a notable decline in TB notifications, dropping from 11,402 in 2019 to approximately 10,900 cases annually. In a public health context, this decline was never a sign of victory over the bacteria. Instead, it represented the “silent years” where the machinery of TB surveillance was diverted to manage the COVID-19 emergency.
Deaths, however, moved in the opposite direction. They rose from 266 in 2019 to 295 in 2020 and peaked at 310 in 2021. This increase during a period of lower reported cases is concerning: it suggests that the patients who did reach care were often diagnosed late, or that ongoing treatment was interrupted. In Jammu & Kashmir’s context, with its mix of urban centers like Srinagar and Jammu and far-flung rural and high-altitude areas, such patterns point to fragile follow-up systems that struggled under pandemic pressure.
Lower reporting activity and the suspension of active screening campaigns meant that for two years, the transmission chain continued largely unmonitored.
By 2022, case numbers stabilized at 10,915 before climbing to 11,754 in 2023. This rebound does not necessarily signal a surge in actual disease transmission. Instead, it aligns with restored healthcare operations, stronger implementation of digital tracking tools like Nikshay, and renewed emphasis on active case finding. In a state with pronounced district-level disparities, improved reporting likely brought previously undetected cases into the system.
Yet the mortality data for 2023 delivers a stark warning: deaths jumped sharply to 435 the highest in the dataset provided by the MInistry of Health and Family Welfare in Rajya Sabha. This 2023 surge serves as a “lagging indicator.” It suggests that the cases missed during 2020 and 2021 did not disappear; rather, they progressed. By the time these patients entered the system in 2023, many were likely at an advanced stage of the disease, suffering from treatment interruptions or unmanaged co-morbidities. Possible contributing factors include interruptions in drug supply or adherence and access barriers that remain acute in remote districts even when overall systems recover.
The rise in notifications to 11,754 in 2023 and the subsequent peak of 11,950 in 2025 should be viewed through the lens of improved state capacity. Rather than indicating a sudden explosion in TB spread, these numbers likely reflect the success of aggressive outreach and digital tracking.
Encouragingly, deaths fell to 313 in the first ten months of 2024. If this lower rate held for the remainder of the year, it would represent a meaningful improvement over 2023. This decline could reflect better treatment adherence, more consistent drug availability, enhanced patient tracking, or earlier diagnosis as health infrastructure stabilized further. The contrast between high cases and relatively lower deaths (compared to the 2023 spike) hints at possible gains in the quality of care delivery, even if the overall burden stays heavy.
The data reveals three broad phases: pre-pandemic stability followed by disruption, cautious recovery with improved detection, and a continuing high plateau. The pandemic exposed and amplified existing weaknesses in healthcare access and continuity of care. The post-2022 rise in notifications, paired with volatile mortality, suggests a system that is getting better at finding cases but still contends with challenges in ensuring successful outcomes for all.
Looking ahead, the modest mortality improvement in 2024 offers a basis for cautious optimism if it can be sustained and expanded. Maintaining momentum in active case finding while strengthening follow-up mechanisms, particularly in hard-to-reach areas, appears critical. The 2025 case total shows that Tuberculosis remains a priority public health issue requiring consistent political attention and resource focus.
For the Union Territory to move toward its elimination targets, the focus must now shift from merely finding cases to ensuring treatment adherence.
Going forward, the high notification rates will test the UT’s healthcare infrastructure, specifically its ability to provide consistent drug supplies and nutritional support to nearly 12,000 patients annually. Whether it can now straighten the curve, translating better detection and recent mortality gains into a sustained downward trend in both cases and deaths, will define the next chapter in the state’s effort to control this long-standing disease.
